Helmholtz Gemeinschaft


In-depth cell-free DNA sequencing reveals genomic landscape of Hodgkin’s lymphoma and facilitates ultrasensitive residual disease detection

Item Type:Article
Title:In-depth cell-free DNA sequencing reveals genomic landscape of Hodgkin’s lymphoma and facilitates ultrasensitive residual disease detection
Creators Name:Sobesky, S. and Mammadova, L. and Cirillo, M. and Drees, E.E.E. and Mattlener, J. and Dörr, H. and Altmüller, J. and Shi, Z. and Bröckelmann, P.J. and Weiss, J. and Kreissl, S. and Sasse, S. and Ullrich, R.T. and Reinke, S. and Klapper, W. and Gerhard-Hartmann, E. and Rosenwald, A. and Roemer, M.G.M. and Nürnberg, P. and Hagenbeek, A. and Zijlstra, J.M. and Pegtel, D.M. and Engert, A. and Borchmann, P. and von Tresckow, B. and Borchmann, S.
Abstract:BACKGROUND: Individualization of treatment in Hodgkin's lymphoma is necessary to improve cure rates and reduce treatment side effects. Currently, it is hindered by a lack of genomic characterization and sensitive molecular response assessment. Sequencing of cell-free DNA is a powerful strategy to understand the cancer genome and can be used for extremely sensitive disease monitoring. In Hodgkin's lymphoma, a high proportion of cell-free DNA is tumor-derived, whereas traditional tumor biopsies only contain a little tumor-derived DNA. METHODS: We comprehensively genotype and assess minimal residual disease in 121 patients with baseline plasma as well as 77 follow-up samples from a subset of patients with our targeted cell-free DNA sequencing platform. FINDINGS: We present an integrated landscape of mutations and copy number variations in Hodgkin's lymphoma. In addition, we perform a deep analysis of mutational processes driving Hodgkin's lymphoma, investigate the clonal structure of Hodgkin's lymphoma, and link several genotypes to Hodgkin's lymphoma phenotypes and outcome. Finally, we show that minimal residual disease assessment by repeat cell-free DNA sequencing, as early as a week after treatment initiation, predicts treatment response and progression-free survival, allowing highly improved treatment guidance and relapse prediction. CONCLUSIONS: Our targeted cell-free DNA sequencing platform reveals the genomic landscape of Hodgkin's lymphoma and facilitates ultrasensitive detection of minimal residual disease.
Keywords:Cancer, CAT Scale: Translation to Patients, Cell-Free DNA, Circulating DNA, Genomics, Hodgkin Lymphoma, Liquid Biopsy, Lymphoma, Minimal Residual Disease, Response Assessment
Publisher:Cell Press
Page Range:1171-1193
Date:8 October 2021
Official Publication:https://doi.org/10.1016/j.medj.2021.09.002
PubMed:View item in PubMed

Repository Staff Only: item control page

Open Access
MDC Library